acetylcysteine

Trade name: mucomyst

Small moleculeapproved

Approved

Sep 14, 1963

Acetylcysteine (also known as N-acetylcysteine or N-acetyl-L-cysteine or NAC) is primarily used as a mucolytic agent and in the management of acetaminophen poisoning. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite. Nacystelyn (NAL), a recently-developed lysine salt of N-acetylcysteine (NAC) is known to have excellent mucolytic capabilities and is used to treat cystic fibrosis (CF) lung disease. NAC as a precursor to the antioxidant glutathione modulates glutamatergic, neurotrophic, and inflammatory pathways. The potential applications of NAC to facilitate recovery after traumatic brain injury, cerebral ischemia, and in treatment of cerebrovascular vasospasm after subarachnoid hemorrhage. Acetylcysteine serves as a prodrug to L-cysteine, which is a precursor to the biologic antioxidant, glutathione, and hence administration of acetylcysteine replenishes glutathione stores. L-cysteine also serves as a precursor to cystine, which in turn serves as a substrate for the cystine-glutamate antiporter on astrocytes hence increasing glutamate release into the extracellular space. Acetylcysteine also possesses some anti-inflammatory effects possibly via inhibiting NF-κB through redox activation of the nuclear factor kappa kinases thereby modulating cytokine synthesis. NAC is associated with reduced levels of inflammatory cytokines and acts as a substrate for glutathione synthesis. These actions are believed to converge upon mechanisms promoting cell survival and growth factor synthesis, leading to increased neurite sprouting. — NCATS

Clinical trial activity

534 trials · 454 clinical orgs · 28 marketing orgs

Phase 1
115
Phase 2
219
Phase 3
98
Phase 4
94

Earliest trial started Jan 1, 1997 (NCT00205647)

Timeline

1960s

  1. Sep 14, 1963

    Apothecon — Earliest FDA Approval

  2. Sep 14, 1963

    Apothecon — NDA Secondary Org

  3. Sep 14, 1963

    Apothecon — NDA Organization

1980s

  1. Oct 14, 1986

    Dey — Marketing Organization

  2. May 1, 1989

    Hospira — Marketing Organization

1990s

  1. Apr 30, 1992

    Roxane Laboratories — Marketing Organization

  2. Apr 30, 1992

    Boehringer Ingelheim — Marketing Organization

  3. Jul 28, 1995

    Sankyo — Marketing Organization

  4. Jul 28, 1995

    Lutipold — Marketing Organization

  5. Jan 1, 1997

    Earliest Phase 2 Sponsor(trial)

  6. Jan 1, 1998

    Earliest Phase 3 Sponsor(trial)

2000s

  1. Jan 1, 2003

    Earliest Phase 1 Sponsor(trial)

  2. Jan 23, 2004

    Cumberland Pharmaceuticals — NDA Secondary Org

2010s

  1. Jun 21, 2012

    Alvogen — Marketing Organization

  2. Nov 7, 2012

    Fresenius — Marketing Organization

  3. Mar 24, 2015

    Akorn, Inc. — Marketing Organization

  4. Jun 19, 2015

    Rising Pharmaceuticals — Marketing Organization

  5. Jun 19, 2015

    Mylan — Marketing Organization

  6. Jan 29, 2016

    Arbor Pharmaceuticals — NDA Secondary Org

  7. Feb 29, 2016

    Aurobindo Pharma — Marketing Organization

  8. Feb 29, 2016

    Eugia Pharma — Marketing Organization

  9. Oct 31, 2017

    Sagent Pharmaceuticals, Inc. — Marketing Organization

  10. Oct 31, 2017

    Nichi-Iko Pharmaceutical Co., Ltd. — Marketing Organization

  11. Jul 20, 2018

    Zydus Discovery DMCC — Marketing Organization

2020s

  1. Apr 15, 2021

    Exela Pharma Sciences, LLC. — Marketing Organization

  2. Feb 3, 2022

    Aspen Pharmaceuticals — Marketing Organization

  3. Feb 3, 2022

    Glenmark Pharmaceuticals — Marketing Organization

  4. Feb 23, 2022

    Indoco Remedies — Marketing Organization

  5. Apr 19, 2023

    STERISCIENCE — Marketing Organization

  6. Feb 13, 2024

    GALEPHAR — Marketing Organization

  7. Jun 7, 2024

    Somerset Pharmaceuticals — Marketing Organization

Indications

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Mycolytic

    Mucolytic agent, cleaves disulfide linkages reducing mucous viscosity. May also have a role in managing the oxidant burden.

  • Unspecified targetOTHER

    Glutathione precursor

    Antidote for acetaminophen overdose. Upon overdose, significant amounts of a reactive intermediate are formed which reacts with glutathione, depleting hepatic glutathione stores, and then reacts with hepatocyte proteins. Acetylcysteine provides an alternative substrate for conjugation with the reactive intermediate potentially restoring glutathione levels.

  • Unspecified targetAntioxidant

    antioxidant

Combination products

Approval history

  • approvedPriority reviewSep 14, 1963

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)N[C@@H](CS)C(O)=O
Mol. weight
163.195 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral, Topical
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

Yes

Sources

Also known as

  • (2r)-2-acetylamino-3-sulfanylpropanoic acid
  • (2r)-2-acetylamino-3-sulfanylpropanoic acid
  • 5052
  • acc-600
  • acetadote
  • acetadote
  • acetadote
  • acetadote
  • acetilcisteina
  • acetilcisteina
  • acetilcysteina
  • acetylcysteine
  • acetylcysteine
  • acetylcysteine
  • acetylcysteine
  • acetylcysteine
  • acetylcysteine
  • acetylcysteine
  • acetylcysteine
  • acetylcysteine
  • acetylcysteine
  • acetylcysteinum
  • acetylcysteinum
  • acteylcysteine
  • a-cys
  • airbron
  • airbron
  • ar10
  • en-cys
  • fabrol
  • fabrol
  • fluimucil
  • fluimucil
  • fluimucil
  • fluimucil 600
  • fluimucil long
  • fluimucil n
  • ilube
  • ilube
  • l-acetylcysteine
  • l-acetylcysteine
  • l-acetylcysteine
  • l-α-acetamido-β-mercaptopropionic acid
  • l-α-acetamido-β-mercaptopropionic acid
  • mercapturic acid
  • mercapturic acid
  • mucomyst
  • mucomyst
  • mucosil
  • mucosil
  • mucosil-10
  • mucosil-10
  • mucosil-20
  • mucosil-20
  • nac
  • nac
  • n-acetylcysteine
  • n-acetylcysteine
  • n-acetylcysteine
  • n-acetyl cysteine
  • n-acetyl cysteine
  • n-acetyl-cysteine
  • n-acetyl-cysteine
  • n-acetylcystine
  • n-acetylcystine
  • n-acetyl-l-cysteine
  • n-acetyl-l-cysteine
  • n-acetyl-l-cysteine
  • n-acetyl-l-cysteine
  • n-acetyl-l-(+)-cysteine
  • n-acetyl-l-(+)-cysteine
  • n-monoacetylcystine
  • oronac 600
  • parvolex
  • parvolex
  • parvolex
  • (r)-2-acetylamino-3-mercaptopropanoic acid
  • (r)-2-acetylamino-3-mercaptopropanoic acid
  • respi-nac
  • (r)-mercapturic acid
  • (r)-mercapturic acid
  • siran
  • siran
  • solmucol
  • solmucol
  • yournac

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07227649Phase 2Jan 15, 2026University of Arizona
NCT07301294Phase 4Jan 1, 2026Menoufia University
NCT07293884N/ADec 31, 2025Assiut University
NCT07049952Phase 2/Phase 3 (Phase 3)Nov 16, 2025Medical University of South Carolina, National Institutes of Health (NIH)
NCT07262554Phase 2Nov 15, 2025Alexandria University
NCT06956482Phase 3Oct 31, 2025University of Lille
NCT07196852N/ASep 22, 2025University of Thessaly
NCT07156786Phase 2/Phase 3 (Phase 3)Sep 15, 2025University of Indonesia
NCT07245095Phase 2Sep 12, 2025Hospital General de Mexicali
NCT07157722Phase 3Aug 30, 2025Mansoura University, Tanta University
NCT07058090Phase 1Jul 31, 2025Liaquat University of Medical & Health Sciences
NCT06890507Phase 2Jun 1, 2025University of Adelaide
NCT06909799N/AApr 28, 2025Aurum Institute, Ludwig Maximilians University, Research Center Borstel
NCT06727422Phase 2Apr 1, 2025Cedars-Sinai Medical Center
NCT06836128Phase 3Mar 1, 2025Cairo University
NCT06828120Phase 4Feb 20, 2025Government of China, Taipei Veteran General hospital
NCT06581783N/ANov 1, 2024Asian Institute of Gastroenterology
NCT06650384Phase 2/Phase 3 (Phase 3)Nov 1, 2024Ain Shams University
NCT07229456Phase 3Oct 1, 2024Ain Shams University
NCT06546475Phase 4Aug 1, 2024National Taiwan University
Showing 20 of 534 trials
Page 1 / 27

Organizations

Research & Development (454)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Medical University of South CarolinaAcademic/Hospital241242003
Ain Shams UniversityAcademic/Hospital191752013
Department of Veteran AffairsGovernment171052003
National Institutes of Health (NIH)Government17152007
University of MinnesotaAcademic/Hospital13942006
Baylor UniversityAcademic/Hospital121232006
Harvard UniversityAcademic/Hospital12932003
University of South CarolinaAcademic/Hospital121242006
Yale UniversityAcademic/Hospital11932006
Assiut UniversityAcademic/Hospital101052007
National Institute on Drug Abuse (NIDA)Government9132003
University of California, San FranciscoAcademic/Hospital9832009
University of TorontoAcademic/Hospital9952002
Cairo UniversityAcademic/Hospital8552015
Stanford UniversityAcademic/Hospital8722008
Tel Aviv UniversityAcademic/Hospital8742003
University of Sao PauloAcademic/Hospital8832005
Cornell UniversityAcademic/Hospital7521997
National Institute of Neurological Disorders and Stroke (NINDS)Government7122008
Peking UniversityAcademic/Hospital7722017
454 organizations
Page 1 / 23

Marketing (33)

OrganizationOrg typeRelationshipDate
Akorn, Inc.For profitMKTGMar 24, 2015
Akorn, Inc.For profitSYNMar 24, 2015
AlvogenFor profitMKTGJun 21, 2012
AlvogenFor profitSYNJun 21, 2012
ApotheconFor profitNDA2Sep 14, 1963
ApotheconFor profitNDASep 14, 1963
Arbor PharmaceuticalsFor profitNDA2Jan 29, 2016
Aspen PharmaceuticalsFor profitMKTGFeb 3, 2022
Athenex, Inc.For profitMKTG
Aurobindo PharmaFor profitMKTGFeb 29, 2016
Boehringer IngelheimFor profitMKTGApr 30, 1992
Cumberland PharmaceuticalsFor profitNDA2Jan 23, 2004
DeyFor profitMKTGOct 14, 1986
Eugia PharmaFor profitMKTGFeb 29, 2016
Exela Pharma Sciences, LLC.For profitMKTGApr 15, 2021
FreseniusFor profitMKTGNov 7, 2012
GALEPHARFor profitMKTGFeb 13, 2024
Glenmark PharmaceuticalsFor profitMKTGFeb 3, 2022
HospiraFor profitMKTGMay 1, 1989
Indoco RemediesFor profitMKTGFeb 23, 2022
LutipoldFor profitMKTGJul 28, 1995
Mead JohnsonFor profitNDA2
MylanFor profitMKTGJun 19, 2015
Nichi-Iko Pharmaceutical Co., Ltd.For profitMKTGOct 31, 2017
Rising PharmaceuticalsFor profitMKTGJun 19, 2015
Roxane LaboratoriesFor profitMKTGApr 30, 1992
STERISCIENCEFor profitMKTGApr 19, 2023
STERISCIENCEFor profitSYNApr 19, 2023
Sagent Pharmaceuticals, Inc.For profitSYNOct 31, 2017
Sagent Pharmaceuticals, Inc.For profitMKTGOct 31, 2017
SankyoFor profitMKTGJul 28, 1995
Somerset PharmaceuticalsFor profitMKTGJun 7, 2024
Zydus Discovery DMCCFor profitMKTGJul 20, 2018